BDX

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Becton, Dickinson and Company, covering the three-month period ended December 31, 1997. The company operates in the medical supplies, devices, and diagnostic systems sectors. As of January 31, 1998, there were 122,175,189 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 7% year-over-year. Excluding the unfavorable impact of a stronger U.S. dollar (estimated $26 million reduction), organic revenue growth was approximately 11%.
• Profitability: Net income rose 11% to $64.3 million. Operating income increased 19% to $103.1 million, driven by a 1.7 percentage point improvement in gross profit margin due to a more profitable product mix and productivity gains.
• Segment Performance:
  • Medical Supplies & Devices: Revenues up 7% (11% excluding currency). Domestic revenues surged 18%, while international revenues declined 3% (up 4% excluding currency).
  • Diagnostic Systems: Revenues up 7% (11% excluding currency). Domestic revenues grew 17%, aided by a prior year acquisition in infectious disease diagnostics.
• Expenses: Selling and administrative expenses remained flat as a percentage of revenue (28.4%). Research and development spending increased 13% to $44.6 million.
• Other Income: Other (expense) income was $2.2 million unfavorable compared to a $4.8 million gain in the prior year, primarily due to higher foreign exchange losses and the absence of a one-time gain.

Guidance, Outlook, and Risks

• Acquisitions:
  • Completed acquisition of an ophthalmic surgical and anesthesia products manufacturer for $40 million (estimated annual revenue $22 million).
  • Acquired IntelliCode Intelligent Bar Coding Systems and Tru-Fit Marketing Corporation (aggregate annual revenue ~$28 million).
  • Agreed to acquire the Medical Devices Division of Ohmeda (estimated annual revenue $200 million), expected to close in Q3 1998 pending regulatory approval.
• Capital Allocation:
  • Repurchased 879,000 shares of common stock for $43 million. Authorization remains for an additional 10.7 million shares.
  • Increased quarterly dividend from $0.13 to $0.145 per share.
  • Capital expenditures were $44 million for the quarter; full-year expectations are slightly higher than the prior year's $170 million.
• Accounting Changes:
  • Adopted SFAS No. 128 for Earnings Per Share calculations.
  • Effective Jan 1, 1998, Brazilian operations will no longer be treated as highly inflationary; future translation adjustments will go to equity rather than earnings.
• Risks and Contingencies:
  • Year 2000 Compliance: Estimated cost of $6 million to $10 million to modify systems. Completion expected by mid-1999. Risks include potential failures in third-party systems.
  • Foreign Currency: Continued volatility in exchange rates impacts reported revenue and earnings.
  • Regulatory: Changes in health care regulations and government approvals for acquisitions.

Investor Verification Checklist

• Verify the closing timeline and regulatory approval status of the $200 million Ohmeda Medical Devices Division acquisition.
• Monitor the impact of the stronger U.S. dollar on future international revenue growth, which currently masks underlying organic growth.
• Review the progress and cost containment of the Year 2000 computer system remediation program.
• Assess the integration and revenue contribution of recent smaller acquisitions (IntelliCode, Tru-Fit, ophthalmic/anesthesia manufacturer).
• Confirm the sustainability of the improved gross profit margin (49.4%) amidst rising R&D investments.